RxDoctor Payments Data

Tori Robinson, APRN

Family · Brownsville, KYNPI 1639283963

Payments from drug & device makers

$1,996in general payments, 2019–2025

Across 122 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$447
  • GSK$288
  • Lilly USA, LLC$226
  • Mylan Specialty L.p.$163
  • Biohaven Pharmaceuticals, Inc.$156
  • Bayer$105
  • plus $611 from 14 others

What the payments were for

  • Food & beverage$1,996100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,996 in reported general payments places this provider in the 75th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$7,401
Medicare patients
143
Services billed
703

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide146$160,202
Trelegy ElliptaFluticasone/Umeclidin/Vilanter159$148,048
EliquisApixaban142$96,614
FarxigaDapagliflozin Propanediol115$93,313
JardianceEmpagliflozin99$77,396
JanuviaSitagliptin Phosphate86$74,222
Breztri AerosphereBudesonide/Glycopyr/Formoterol40$44,800
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog65$44,070
TrulicityDulaglutide37$40,400
Breo ElliptaFluticasone/Vilanterol79$37,454
RybelsusSemaglutide15$23,131
MounjaroTirzepatide21$22,299
Ondansetron Hcl28$15,320
Tresiba Flextouch U-100Insulin Degludec14$14,715
Lantus SolostarInsulin Glargine,hum.Rec.Anlog80$14,014

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$288$197,291263 claims
Novo NordiskOzempic, Rybelsus$100$183,333161 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$447$148,644174 claims
PfizerEliquis$36$96,614142 claims
MerckJanuvia, Steglatro$102$78,31098 claims
Lilly USA, LLCTrulicity, Mounjaro$226$62,69958 claims
AbbVieCreon, Synthroid$38$7,05688 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,374 family providers in Kentucky.

Other family in Brownsville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →